Statin Combined With Amlodipine Treats Primary Aldosteronism

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 180 participants.

Also called NCT06523465

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06523465
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06523465. Randomized; no masking; primary purpose treatment. Start 2024-09-10 (actual); primary completion 2026-11-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Statin Combined With Amlodipine Treats Primary Aldosteronism
Acronym
STOP-PA
Condition
Primary Aldosteronism
Condition
Statin
Condition
Hypertension
Intervention (Drug)
Simvastatin combined with Amlodipine besylate
Intervention (Drug)
Simvastatin combined with Spironolactone and Amlodipine besylate.
Intervention (Drug)
Amlodipine besylate combined Spironolactone
Lead sponsor
Third Military Medical University (class: other)

Record details

Record id
cardio:ct-nct06523465
Content hash
528568212685033cbf255616d463ad94f5719f040983268646b793d7a41f86f7